Sign In
Buy INCY
$107.53
-0.93 (-0.86%)
At Close: Jun 25, 2026
Futures are trading mixed as we prepare to finish the last full week of the second quarter.
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
10:51am, Friday, 19'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or Refractory DLBCL.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
07:51am, Wednesday, 17'th Jun 2026
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
04:56am, Tuesday, 16'th Jun 2026
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
11:45am, Monday, 15'th Jun 2026
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF &
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Results from Incyte's frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survi
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings
01:48pm, Thursday, 11'th Jun 2026
Biotech stock Incyte is working its way up toward a pivot at 112.29, extending a two-day winning streak.
Here's Why Incyte (INCY) is a Strong Value Stock
10:40am, Thursday, 11'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Chip Weakness, Middle East Concerns Drag Dow 549 Points
12:00pm, Wednesday, 10'th Jun 2026
Stocks are firmly lower as the chip stocks and Iran tensions weigh, while investors unpack this morning's CPI data
